Stock Watch: Oncology Heritage Impedes Roche's Growth

Telavant Acquisition Is No Slam-Dunk To Turn Around Weak Sales

 
• By Andy Smith
  
Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

More from Stock Watch

More from Business